In a significant move for Vera Therapeutics, Inc. (NASDAQ: VERA), analyst Andy Chen from Wolfe Research has initiated an “Outperform” rating as of March 11, 2026. This upgrade comes with a notably ambitious price target of $88, signaling a strong belief in the company’s future potential. For investors, this valuation suggests significant upside from the current trading price of $40.25, sparking renewed interest in the stock amid an evolving market landscape.
Recent Price Action
Vera Therapeutics has demonstrated notable trading behavior recently, with its stock price slightly retreating by $0.19, marking a decline of 0.47% on the most recent trading day. Trading at $40.25, VERA is currently positioned significantly below its 52-week high of $128.55, reflecting a substantial dip over the past year. The stock’s recent volatility, with a weekly volatility measure of 6 and a monthly volatility of 5.25, indicates an environment of uncertainty for investors. Moreover, trading volume for VERA has been above average with 553,722 shares changing hands, although this is notably less than its three-month average of approximately 1.11 million shares. This market cap currently stands at around $2.86 billion with a beta of 1.169, hinting at the stock’s responsiveness to broader market changes.
Historical Performance
Examining Vera’s performance, the stock has shown mixed results across different time frames. Over the last 30 days, VERA has experienced a decline of 7.62%, highlighting potential headwinds in the short term. However, the stock rallies in a quarterly view, showcasing a compelling return of 43.55%, bolstered by investor optimism during that period. Year-over-year, VERA boasts a respectable gain of 36.76%, suggesting that despite recent setbacks, the stock has been able to grow amidst challenging market conditions. Additionally, its average trading volume over the last 10 days further underscores investor interest and engagement, with an average volume of around 1.3 million shares.
Earnings Analysis
On the earnings front, Vera Therapeutics recently released its latest earnings per share (EPS) data, reporting an EPS of -$1.26, which fell short of the estimated EPS of -$1.20. This resulted in a surprise factor of a -5%, reflecting challenges in meeting earnings expectations. Comparatively, in its previous earnings report in August 2025, VERA had an EPS of -$1.20 against an estimate of -$0.82, resulting in an earnings surprise of 46.34% that had positively influenced investor sentiment at that time. The current disappointment reinforces the importance of continuous operational improvements and the need for clearer pathways to profitability.
Analyst / Consensus View
The sentiment surrounding VERA is overwhelmingly positive based on consensus ratings. Wolfe Research’s recent rating adjustment aligns with a clear all-bullish stance, as all five analysts covering Vera Therapeutics recommend the stock as a ‘Buy,’ with none suggesting a ‘Hold’ or ‘Sell.’ The average price target among analysts has been pegged at $91.60, while the range of targets varies from a conservative low of $66 to an ambitious high of $110. Such a consensus reflects a widespread belief in the company’s growth prospects, reinforced by the recent upgrade to “Outperform.”
Stock Grading or Fundamental View
Vera Therapeutics carries a Stocks Telegraph (ST) grading score of 44, indicating a moderately favorable financial stance. The ST score condenses various metrics into a single evaluation, offering insight into Vera’s financial health and market position. A score of 44 suggests that while there are promising elements regarding financial stability and growth potential, there remains room for improvement and vigilance, particularly in the execution of its operational strategies.
Conclusion
For investors contemplating a position in Vera Therapeutics, the stock presents a compelling opportunity for those leaning towards growth-oriented investing. With a notable upside potential highlighted by Wolfe Research’s upgrade and a consensus bullish outlook, VERA could be particularly attractive for long-term investors with an appetite for risk. However, prospective investors should remain cautious about the recent underperformance in earnings and the inherent volatility of the biotech sector, which can introduce significant risks. Keeping a close eye on forthcoming earnings reports and developments will be crucial for making informed investment decisions in this dynamic market environment.